Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Our finding of similar incidence of non-fatal cardiovascular outcomes with GLP1-RA compared to DPP4i is in line with the recently published FLOW study that randomized people with early to mid-stage CKD to semaglutide or placebo, which reported similar incidence of non-fatal myocardial infarction and non-fatal stroke across the semaglutide and placebo treated groups, despite a significantly reduced risk of major kidney disease events and all-cause death 44
Weight change: 1-2 pounds this week (15-19 pounds total, approximately 8.7% of starting weight)
www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity Schreiber, J
BMI is calculated by dividing a persons weight in kilograms by the square of their height in meters, providing a standardized measure of body fatness
Laboratory research record on GLP-1S [PMID: 31747740] PubMed laboratory record discussing GLP-1S in a research context
